Post-Renal Transplant Diabetes Mellitus in Korean Subjects: Superimposition of Transplant-Related Immunosuppressant Factors on Genetic and Type 2 Diabetic Risk Factors

다국어 초록 (Multilingual Abstract)

Postrenal transplantation diabetes mellitus (PTDM), or new-onset diabetes after organ transplantation, is an important chronic transplant-associated complication. Similar to type 2 diabetes, decreased insulin secretion and increased insulin resistance are important to the pathophysiologic mechanism behind the development of PTDM. However, β-cell dysfunction rather than insulin resistance seems to be a greater contributing factor in the development of PTDM. Increased age, family history of diabetes, ethnicity, genetic variation, obesity, and hepatitis C are partially accountable for an increased underlying risk of PTDM in renal allograft recipients. In addition, the use of and kinds of immunosuppressive agents are key transplant-associated risk factors. Recently,a number of genetic variants or polymorphisms susceptible to immunosuppressants have been reported to be associated with calcineurin inhibition-induced β-cell dysfunction. The identification of high risk factors of PTDM would help prevent PTDM and improve long-term patient outcomes by allowing for personalized immunosuppressant regimens and by managing cardiovascular risk factors.

참고문헌 (Reference)

1 Fraenkel M, "mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes" 57 : 945-957, 2008

2 Nam JH, "beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus" 71 : 1417-1423, 2001

3 Kang ES, "Variants of the adiponectin and adiponectin receptor-1 genes and posttransplantation diabetes mellitus in renal allograft recipients" 97 : E129-E135, 2012

4 Crutchlow MF, "Transplant-associated hyperglycemia: a new look at an old problem" 2 : 343-355, 2007

5 이상열, "The Prediabetic Period: Review of Clinical Aspects" 대한당뇨병학회 35 (35): 107-116, 2011

6 Uchizono Y, "Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling" 145 : 2264-2272, 2004

7 Arner P, "Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy" 6 : 23-25, 1983

8 Zhang N, "Sirolimus is associated with reduced islet engraftment and impaired beta-cell function" 55 : 2429-2436, 2006

9 Jeong KH, "Significant associations between CCL5 gene polymorphisms and posttransplantational diabetes mellitus in Korean renal allograft recipients" 32 : 356-361, 2010

10 Polastri L, "Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells" 39 : 229-233, 2002

11 Hur KY, "Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients" 30 : 609-615, 200703

12 Lawrence MC, "Regulation of insulin gene transcription by a Ca(2+)-responsive pathway involving calcineurin and nuclear factor of activated T cells" 15 : 1758-1767, 2001

13 Shimodahira M, "Rapamycin impairs metabolism-secretion coupling in rat pancreatic islets by suppressing carbohydrate metabolism" 204 : 37-46, 2010

14 Sumrani N, "Posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients" 23 (23): 1249-1250, 1991

15 Lee HC, "Posttransplant diabetes mellitus after renal transplantation in Korea" 28 : 1159-1160, 1996

16 von Kiparski A, "Post-transplant diabetes mellitus in renal allograft recipients: a matched-pair control study" 5 : 220-225, 1990

17 Rao M, "Post-renal transplant diabetes mellitus: a retrospective study" 7 : 1039-1042, 1992

18 Lanerolle RD, "Post-renal transplant diabetes in Sri Lanka" 28 : 1945-1947, 1996

19 Dutkiewicz G, "Polymorphisms of superoxide dismutase, glutathione peroxidase and catalase genes in patients with posttransplant diabetes mellitus" 41 : 350-355, 2010

20 Chang HR, "Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus" 412 : 322-326, 2011

21 Markell M, "New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management" 43 : 953-965, 2004

22 Bloom RD, "New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies" 3 (3): S38-S48, 2008

23 Veroux M, "New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression" 40 : 1885-1887, 2008

24 Rodrigo E, "New-onset diabetes after kidney transplantation: risk factors" 17 (17): S291-S295, 2006

25 Heisel O, "New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis" 4 : 583-595, 2004

26 Lawrence MC, "NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1" 51 : 691-698, 2002

27 Kim DJ, "Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus" 50 : 590-593, 2001

28 Midtvedt K, "Insulin resistance is a common denominator of post-transplant diabetes mellitus and impaired glucose tolerance in renal transplant recipients" 13 : 427-431, 1998

29 Ekstrand AV, "Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man" 53 : 563-569, 1992

30 Paty BW, "Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets" 73 : 353-357, 2002

31 Oetjen E, "Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice" 63 : 1289-1295, 2003

32 Heaton DA, "Increased proinsulin levels as an early indicator of B-cell dysfunction in non-diabetic twins of type 1 (insulin-dependent) diabetic patients" 31 : 182-184, 1988

33 Woodward RS, "Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients" 3 : 590-598, 2003

34 Shimizu M, "Improvement of insulin sensitivity after renal transplantation measured by a glucose clamp technique" 65 : 50-54, 1998

35 Hill CM, "Glycosuria and hyperglycaemia after kidney transplantation" 2 : 490-492, 1974

36 Tsai JP, "Glutathione S-transferase gene polymorphisms are not major risks for susceptibility to posttransplantation diabetes mellitus in Taiwan renal transplant recipients" 25 : 432-435, 2011

37 Hjelmesaeth J, "Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age" 64 : 979-983, 1997

38 Chen Y, "Genetic polymorphisms of the transcription factor NFATc4 and development of new-onset diabetes after transplantation in Hispanic kidney transplant recipients" 93 : 325-330, 2012

39 Yang J, "Genetic and clinical risk factors of new-onset diabetes after transplantation in Hispanic kidney transplant recipients" 91 : 1114-1119, 2011

40 Starzl TE, "Factors in successful renal transplantation" 56 : 296-318, 1964

41 Redmon JB, "Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HITT15 cells" 98 : 2786-2793, 1996

42 Szuszkiewicz M, "ENPP1/PC-1 K121Q and other predictors of posttransplant diabetes" 9 : 25-29, 2011

43 Roder ME, "Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus" 83 : 604-608, 1998

44 Nielsen JH, "Direct effects of cyclosporin A on human pancreatic beta-cells" 35 : 1049-1052, 1986

45 Miles AM, "Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes?" 65 : 380-384, 1998

46 Sumrani NB, "Diabetes mellitus after renal transplantation in the cyclosporine era: an analysis of risk factors" 51 : 343-347, 1991

47 Basri N, "Diabetes mellitus after renal transplantation" 24 : 1780-1781, 1992

48 Kasiske BL, "Diabetes mellitus after kidney transplantation in the United States" 3 : 178-185, 2003

49 Robertson RP, "Cyclosporin-induced inhibition of insulin secretion in isolated rat islets and HIT cells" 35 : 1016-1019, 1986

50 Yu SJ, "Correlation between HLA and posttransplantation diabetes mellitus in the Han population in South China" 42 : 2509-2512, 2010

51 Ahn KJ, "Clinical characteristics and possible risk factors in postrenal transplant diabetes mellitus" 24 : 1581-1582, 1992

52 Numakura K, "Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus" 80 : 1419-1424, 2005

53 Heit JJ, "Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function" 443 : 345-349, 2006

54 Bloom RD, "Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus" 13 : 1374-1380, 2002

55 Kang ES, "Association of Common Type 2 Diabetes Risk Gene Variants and Posttransplantation Diabetes Mellitus in Renal Allograft Recipients in Korea" 88 (88): 693-698, 200901

56 Tavira B, "Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus" 105 : 525-527, 2012

57 Kang ES, "A variant of the transcription factor 7-like 2 (TCF7L2) gene and the risk of posttransplantation diabetes mellitus in renal allograft recipients" 31 (31): 63-68, 200801

58 Kang ES, "A polymorphism in the zinc transporter gene SLC3OA8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients" 57 (57): 1043-1047, 200804

59 Kim I, "A low-risk ZnT-8 allele (W325) for post-transplantation diabetes mellitus is protective against cyclosporin A-induced impairment of insulin secretion" 11 : 191-198, 2011

60 Hagen M, "A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients" 18 : 2154-2159, 2003